

# RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026

## CEO Shaun Bagai to Discuss RenovoRx's Commercial and Clinical Program Progress

MOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- **RenovoRx, Inc. (Nasdaq: RNXT)** ("RenovoRx" or "the Company"), a life sciences company developing innovative targeted oncology therapies and commercializing **RenovoCath®**, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will participate in the AlphaNorth Capital Event. The conference will be held from January 16-18, 2026.

Mr. Bagai will share an update on RenovoRx's commercial progress, fueled by increasing demand for RenovoCath® as a standalone targeted drug-delivery device. Adoption is growing among both new and returning customers, including top cancer centers, highlighting the expanding need for localized, targeted treatment made possible through RenovoRx's proprietary **Trans-Arterial Micro-Perfusion (TAMP™)** therapy platform.

He will also discuss RenovoRx's ongoing Phase III TIGeR-PaC clinical trial evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath in patients with locally advanced pancreatic cancer (LAPC), along with its post-marketing observational registry designed to collect real-world safety and survival data across solid tumors. In addition, Mr. Bagai will highlight RenovoRx's support of capital-efficient, investigator-initiated trials in borderline resectable and metastatic pancreatic cancer, which may further expand the clinical utility of the TAMP™ therapy platform.

### **AlphaNorth Capital Event Details:**

**Date:** January 16-18, 2026

**Location:** Grand Hyatt Baha Mar, Nassau, Bahamas

To schedule a one-on-one investor meeting with Mr. Bagai, please contact KCSA Strategic Communications at [RenovoRx@KCSA.com](mailto:RenovoRx@KCSA.com).

### **About RenovoCath**

Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use ("IFU"), please see: [IFU-10004-Rev.-G-Universal-IFU.pdf](https://www.renovorx.com/IFU-10004-Rev.-G-Universal-IFU.pdf).

### **About RenovoRx, Inc.**

**RenovoRx, Inc. (Nasdaq: RNXT)** is a life sciences company developing innovative targeted

oncology therapies and commercializing **RenovoCath®**, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device, targeting high unmet medical needs. RenovoRx's patented **Trans-Arterial Micro-Perfusion (TAMP™)** therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. RenovoRx's novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.

In addition to the RenovoCath device, RenovoRx is also evaluating its novel drug-device combination oncology product candidate (intra-arterial gemcitabine delivered via RenovoCath, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of the FDA) under a U.S. investigational new drug application that is regulated by the FDA's 21 CFR 312 pathway. IAG utilizes RenovoCath, the Company's patented, FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

The combination product candidate (IAG), which is enabled by the RenovoCath device, is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA.

RenovoRx is also actively commercializing its TAMP technology and FDA-cleared RenovoCath as a stand-alone device. In December 2024, RenovoRx announced the receipt of its first commercial purchase orders for RenovoCath devices. Additionally, several of these customers have already initiated repeat orders in parallel to RenovoRx expanding the number of medical institutions initiating new RenovoCath orders, including several esteemed, high-volume National Cancer Institute-designated centers. To meet and satisfy the anticipated demand, RenovoRx will continue to actively explore further revenue-generating activity, either on its own or in tandem with a medical device commercial partner.

For more information, visit [www.renovorx.com](http://www.renovorx.com). Follow RenovoRx on [Facebook](#), [LinkedIn](#), and [X](#).

#### **Cautionary Note Regarding Forward-Looking Statements**

This press release, the conference presentation described herein, and statements of the Company's management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, (ii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases, and (iii) our efforts to commercialize our RenovoCath and TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control, and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates,

projections, and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives, and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as "may," "expects," "plans," "aims," "anticipates," "believes," "forecasts," "estimates," "intends," and "potential," or the negative of these terms or other comparable terminology regarding RenovoRx's expectations strategy, plans, or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding-; (iii) the timing of the initiation, progress, and potential results (including the results of interim analyses) of our preclinical studies, clinical trials, and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate-; (v) that the applicable regulatory authorities may disagree with our interpretation of the data-, research, and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates, and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage, and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled "Risk Factors" in documents that we file from time to time with the Securities and Exchange Commission.

Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.

**Contact:**

KCSA Strategic Communications

Valter Pinto or Jack Perkins

T: 212-896-1254

[RenovoRX@KCSA.com](mailto:RenovoRX@KCSA.com)

**RENOVO | RX**

Source: RenovoRx, Inc.